Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. Issue 37 (5th September 2017)

• Record Type: Journal Article
• Authors: Lee, Soyoung; Kim, Han Wool; Lee, Ji Hyen; Kim, Kyung-Hyo
• Is Part Of: Vaccine. Volume 35:Issue 37(2017)
• Page Start: 4960
• Page End: 4965
• Publication Date: 2017-09-05
• Subjects: PPSV23 23-valent pneumococcal polysaccharide vaccine -- IPD invasive pneumococcal diseases -- PCV13 13-valent pneumococcal conjugate vaccine -- OPA opsonophagocytic assay -- MOPA multiplexed OPA -- OBB opsonization buffer B -- BRC Baby rabbit complement -- THY Todd-Hewitt yeast -- GMTs Geometric mean OPA titers -- CIs confidence intervals -- RCDCs reverse distribution curves -- ELISA enzyme-linked immunosorbent assay; Pneumococcal polysaccharide vaccine -- Immunogenicity -- Phagocytosis -- Elderly; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.07.074
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for adults aged ≥65 years. To evaluate functional immune response against the additional 11 serotypes that are included in PPSV23, but not the 13-valent pneumococcal conjugate vaccine (PCV13), serotype-specific anti-pneumococcal antibodies were examined using an opsonophagocytic assay (OPA). Methods: Participants ≥65 years of age that were naïve to the pneumococcal vaccine were enrolled. They were divided into two groups according to their age: group 1 (N = 30; aged 65–74 years) and group 2 (N = 32; aged ≥75 years). The functional antibody response prior to and 4 weeks post-immunization with PPSV23 was determined, using a multiplexed OPA (MOPA) for 11 pneumococcal serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20B, 22F, and 33F). Results: Geometric mean OPA titers (GMTs) to 11 serotypes were significantly increased in both groups post-immunization compared to those prior to immunization. The GMTs for all serotypes were not significantly different between the two groups after immunization. The proportion of subjects with OPA titers post-immunization of ≥8 and ≥64 was 93–100% and 80–100% for the 11 serotypes, respectively, while subjects with a ≥4-fold increase in OPA titers ranged from 9 to 90% for the 11 serotypes. Conclusions: This study revealed that PPSV23 vaccination induced significant functional immune responses to 11 non-PCV13 serotypes in older adults. The MOPA has been shown to be a useful tool for future application in evaluating new PCVs in older adults. The clinical trial registration number is KCT 0001963 (CRIS, https://cris.nih.go.kr/cris/en/ ).